Bridge to Life Showcases VitaSmart HOPE Data at ATC 2026
DULUTH, Ga., June 23, 2026 Bridge to Life Ltd. announced new investigator-initiated research presented at the 2026 American Transplant...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DULUTH, Ga., June 23, 2026 Bridge to Life Ltd. announced new investigator-initiated research presented at the 2026 American Transplant...
CAMBRIDGE, Mass., June 3, 2026 Biogen Inc. announced that 14 abstracts from its expanding nephrology portfolio have been accepted...
